Evidence map›Paper›PMID 22891234›Full record

ArticlePediatrics2012

Mortality and clinical outcomes in HIV-infected children on antiretroviral therapy in Malawi, Lesotho, and Swaziland.

Mark M Kabue, W Chris Buck, Sebastian R Wanless, Carrie M Cox, Eric D McCollum, A Chantal Caviness, Saeed Ahmed, Maria H Kim, Lineo Thahane, Andrew Devlin and 6 more

Abstract read
In one paragraph

Article in Pediatrics, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Guideline
  6. Trial
  7. Trial
  8. Observational
  9. Observational
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Observational
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Mark M KabueBaylor College of Medicine Abbott Fund Children's Clinical Centre of Excellence-Malawi, Private Bag B397, Lilongwe 03, Malawi. mmkabue@gmail.com
W Chris Buck
Sebastian R Wanless
Carrie M Cox
Eric D McCollum
A Chantal Caviness
Saeed Ahmed
Maria H Kim
Lineo Thahane
Andrew Devlin
Duncan Kochelani
Peter N Kazembe
Nancy R Calles
Michael B Mizwa
Gordon E Schutze
Mark W Kline

Funding

Virology CoreP30AI036211 · NIAID · BAYLOR COLLEGE OF MEDICINE · PI SHEARER, WILLIAM THOMAS · 1994 to 2015
$21.7M
BAYLOR INTERNATIONAL PEDIATRIC AIDS INITIATIVED43TW001036 · FIC · BAYLOR COLLEGE OF MEDICINE · PI KLINE, MARK W. · 2000 to 2015
$7.6M
Multidisciplinary Training Program in Pediatric PulmonaryT32HL072748 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI Joseph Michael Collaco · 2003 to 2026
$6.1M
FIC NIH HHS D43 TW001036FIC NIH HHS D43 TW01036NHLBI NIH HHS T32 HL072748NIAID NIH HHS P30 AI036211
6 · The paper itself

Abstract

objectiveTo determine mortality and immune status improvement in HIV-infected pediatric patients on antiretroviral treatment (ART) in Malawi, Lesotho, and Swaziland.

methodsWe conducted a retrospective cohort study of patients aged <12 years at ART initiation at 3 sites in sub-Saharan Africa between 2004 and 2009. Twelve-month and overall mortality were estimated, and factors associated with mortality and immune status improvement were evaluated.

resultsIncluded in the study were 2306 patients with an average follow-up time on ART of 2.3 years (interquartile range 1.5-3.1 years). One hundred four patients (4.5%) died, 9.0% were lost to follow-up, and 1.3% discontinued ART. Of the 104 deaths, 77.9% occurred in the first year of treatment with a 12-month mortality rate of 3.5%. The overall mortality rate was 2.25 deaths/100 person-years (95% confidence interval [CI] 1.84-2.71). Increased 12-month mortality was associated with younger age; <6 months (hazard ratio [HR] = 8.11, CI 4.51-14.58), 6 to <12 months (HR = 3.43, CI 1.96-6.02), and 12 to <36 months (HR = 1.92, CI 1.16-3.19), and World Health Organization stage IV (HR = 4.35, CI 2.19-8.67). Immune status improvement at 12 months was less likely in patients with advanced disease and age <12 months.

conclusionsDespite challenges associated with pediatric ART in developing countries, low mortality and good treatment outcomes can be achieved. However, outcomes are worse in younger patients and those with advanced disease at the time of ART initiation, highlighting the importance of early diagnosis and treatment.

Indexed as

Anti-Retroviral AgentsCD4 Lymphocyte CountChildChild, PreschoolEswatiniFemaleHIV InfectionsHumansInfantLesothoMalawiMaleNutritional StatusAnti-Retroviral Agents

Identifiers

PMID22891234
PMCPMC3962849

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.